RecruitingPsA (Psoriatic Arthritis)
A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis
Eligible age
18–70 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The target population is patients with active psoriatic arthritis. A total of 222 subjects are planned to be included.
Sponsor: InventisBio Co., Ltd
You may qualify if…
- ✓ 1. Subjects voluntarily take part in the study after being fully informed, sign a written informed consent form (ICF), and agree to follow procedures specified in the study protocol;
- ✓ 2. Males and females, 18 to 70 years of age, inclusive at the time of signing of ICF;
- ✓ 3. Have had an psoriatic arthritis of ≥ 3 months in duration prior to signing of ICF;
- ✓ 4. Have had active arthritis, characterized by at least ≥3 tender joints (68 joint tenderness counts) and ≥3 swollen joints (66 joint swelling counts).
You may not qualify if…
- ✕ 1. History of infection as defined in the protocol;
- ✕ 2. Any of the medical diseases or disorders listed in the protocol;
- ✕ 3. Significant, uncontrolled or unstable disease in any organ.
Source: ClinicalTrials.gov · NCT07315061 · last updated 2026-04-22